KOSDAQFood & Beverage353810

Easy Bio

₩4,755▼ 2.66%2026-11-18 close
Market Cap
₩157.3B
Turnover
₩400M
Volume
80K
Shares out.
33.1M
PER
5.0×
PBR
1.4×
EPS
₩985
Dividend Yield
5.08%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩250 per share · Prices as of the 2026-11-18 close

01

Report overview

Easy BIO: Q3 Profit Softens as Feed Additives Grow

Easy BIO grew annual profit for three straight years from 2023 through 2025, but in Q3 2026 revenue rose while net profit attributable to controlling shareholders fell for a second consecutive quarter, making earnings durability the next point to check.

  1. 1

    Revenue reached KRW 476.9 billion in 2025 and operating profit KRW 45 billion, the largest year in the 2022–2025 window. Net profit attributable to controlling shareholders was KRW 27.8 billion.

  2. 2

    Q3 2026 revenue was KRW 140 billion, up 19.8% year on year, but operating profit was KRW 11.5 billion and net profit attributable to controlling shareholders fell to KRW 1.08 billion, down 89.4% from the prior quarter.

  3. 3

    Net profit attributable to controlling shareholders totaled KRW 32.6 billion over the last four quarters (Q4 2025 to Q3 2026), with Q1 2026 as the quarterly peak.

  4. 4

    The business is shifting toward feed additives, with the U.S. subsidiary Devenish Nutrition LLC consolidated in March 2024 and the BioMatrix acquisition announced in early 2026 broadening the North American base.

  5. 5

    The debt-to-equity ratio stood at 188.4% at the end of 2025, with total liabilities of KRW 213.9 billion, down from 305.4% at the end of 2024.

02

Business structure

Easy BIO is a feed company that makes piglet feed and feed additives. The company was spun off from Easy Holdings in 2020 and re-listed on KOSDAQ that June, and it now has 11 consolidated subsidiaries. Easy Holdings and three related parties held 51.53% as of October 6, 2026, so the largest-shareholder stake is high.

The business has two pillars: piglet feed supplied to domestic hog farms, and feed additives that improve livestock performance. Brokerage reports cite feed additives at 78.95% of sales, which means the earnings mix is moving toward additives.

Dedicated piglet-feed production lines and in-house additive production are cited as points of differentiation. The overseas expansion turned on the March 2024 consolidation of the U.S. subsidiary Devenish Nutrition LLC.

In January 2026 the company said its U.S. unit Pathway Intermediates USA had acquired 100% of BioMatrix, a U.S. feed additive company, and plans to apply BioMatrix's polysaccharide coating technology to ruminant additives and widen North American reach through its pet distribution experience.

The company says it exports to more than 40 countries and reaches the U.S., Canada, Europe and Asia through its UK subsidiary. Compared with food-sector peers such as CJ CheilJedang and Harim, the company's additive share is high within livestock feed, so its industry read depends on herd size and raw material prices.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩116.9B₩11.2B9.6%
2025Q4₩129.3B₩13.6B10.5%
2026Q1₩130.7B₩13.2B10.1%
2026Q2₩148.1B₩15.1B10.2%
2026Q3₩140B₩11.5B8.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩155.6B₩16.2B₩9.1B10.4%18.3%198.8%
2023₩165.4B₩20.6B₩15.5B12.5%24.8%160.0%
2024₩384.3B₩32.4B₩19.6B8.4%23.3%305.4%
2025₩476.9B₩45B₩27.8B9.4%25.9%188.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a DART-reported basis, annual revenue rose from KRW 155.6 billion in 2022 to KRW 165.4 billion in 2023 (up 6.3% year on year) and jumped to KRW 384.3 billion in 2024 (up 132.4%).

The 2024 expansion reflects the March 2024 consolidation of the overseas subsidiary Devenish Nutrition LLC, and the company attributed the swing to higher overseas additive sales and timing differences from the consolidation date. Revenue reached KRW 476.9 billion in 2025, up 24.1%.

Operating profit went from KRW 16.2 billion in 2022 to KRW 20.6 billion, KRW 32.4 billion and KRW 45 billion in 2025, and the reported filings describe three consecutive years of increases from 2023 through 2025.

Net profit attributable to controlling shareholders rose from KRW 9.13 billion in 2022 to KRW 27.8 billion in 2025, also three consecutive years of increases from 2023 through 2025.

Net profit including non-controlling interests was KRW 29.3 billion in 2025, a different figure from the controlling-shareholder number, with the gap of roughly KRW 1.5 billion reflecting non-controlling interests.

The operating margin was 10.4% in 2022, 12.5% in 2023, 8.4% in 2024 and 9.4% in 2025, so margins moved up and down even as sales grew. Operating cash flow was KRW -8.12 billion in 2022 and then KRW 33.7 billion, KRW 25.8 billion and KRW 34.7 billion in 2023 to 2025.

Quarterly revenue rose from KRW 116.9 billion in Q3 2025 to KRW 129.3 billion in Q4 2025, KRW 130.7 billion in Q1 2026 and KRW 148.1 billion in Q2 2026. Q3 2026 revenue was KRW 140 billion, up 19.8% year on year, while operating profit was KRW 11.5 billion, down 23.4% from the prior quarter and up 2.6% year on year.

Net profit attributable to controlling shareholders fell to KRW 1.08 billion, down 89.4% from the prior quarter and 87.0% from a year earlier, and it declined for two consecutive quarters from Q2 to Q3 2026.

Operating profit held up while controlling-shareholder profit dropped sharply, so the gap between the two levels widened, and the drivers in non-operating items, taxes and non-controlling interests should be checked in the quarterly report. Net profit attributable to controlling shareholders summed to KRW 32.6 billion over the last four quarters.

05

Industry analysis

Demand for feed additives starts with livestock herd size. In Korea, rising hog herd numbers and higher pork consumption are seen as steadily supporting compound feed demand. Tighter restrictions on antibiotic use are cited as a driver of demand for functional additives. The U.S. is the bigger variable.

Analyst Joon-seo Heo at Eugene Investment & Securities said record U.S. beef prices should lift demand for feed additives. The same analysis said lower grain prices could raise farmers' purchasing power and sustain an improving earnings trend.

On the cycle, lower grain prices are read as favorable for farm economics, while another view warns that raw material costs and the exchange rate could push costs back up. Even in a high-inflation environment, piglet feed and commodity additives are said to be able to pass through cost increases to selling prices.

The competitive position rests on dedicated piglet-feed capacity, in-house additive production, and cost competitiveness from microbial and extract-based additives. Share gains in North American additive markets are the main point brokers are tracking.

Since the 2024 consolidation of overseas subsidiaries, the U.S. livestock value chain has grown in weight, so domestic feed demand and overseas additive demand now run on two cycles at once, which sets the company apart within its sector.

06

Outlook

The company's medium-term direction is set out in its 2026 corporate value enhancement plan, decided on March 31, 2026.

The plan targets a stronger stable earnings base through overseas sales growth, stronger ESG management, and improved capital efficiency and financial structure, and it includes a 25% increase in the dividend amount for the prior fiscal year. The company said the plan may change with business conditions.

According to the WiseReport company monitor, revenue in the first half of 2026 rose 20.8% year on year. Brokerage forecasts for full-year 2026 are dated differently.

In an April 2026 report, Eugene Investment & Securities projected revenue of KRW 510.7 billion (up 7%) and operating profit of KRW 52.5 billion (up 17%), with a first-quarter start and a back-half-weighted pattern.

Reported operating profit was KRW 13.2 billion in Q1, KRW 15.1 billion in Q2 and KRW 11.5 billion in Q3, and revenue exceeded KRW 130 billion in each quarter of 2026 so far, so how the early assumptions were reflected should be compared in the full-year results.

The BioMatrix deal added a pet distribution channel to the North American business, and a product mix shift toward higher-value products is cited as a way to defend profitability.

The fourth-quarter 2026 results will be confirmed in the 2026 annual business report, which will also reveal overseas sales share and the contribution of the consolidated subsidiaries.

07

Valuation

PER
5.0×
PBR
1.4×
ROE
30.9%
EPS
₩985
BPS
₩3,513
Dividend per share
₩250

Valuation should be read alongside earnings scale and the balance sheet. In an April 2026 report, Eugene Investment & Securities said the share price multiple on expected earnings does not yet reflect higher North American additive share and the effect of the exchange rate. That is the brokerage's view.

Because net profit attributable to controlling shareholders totaled KRW 32.6 billion over the last four quarters and fell sharply in Q3 2026, multiples move sensitively with changes in earnings level.

The price-to-book level sits at a premium to controlling-shareholder equity of KRW 107.2 billion, and it is usually read by where it sits within the past trading range.

On the balance sheet, total liabilities of KRW 213.9 billion exceed total equity of KRW 113.6 billion, so price-to-book comparisons should be read together with the debt structure and interest burden.

Dividends are one pillar of the value enhancement plan, and whether the dividend yield sits above or below the sector average depends on the comparison date and basis.

Over several years, net profit attributable to controlling shareholders rose from KRW 9.13 billion in 2022 to KRW 27.8 billion in 2025, a clear recovery in earnings, while the Q3 2026 decline will determine whether that trend continues.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Multi-year expansion in profit

Operating profit rose from KRW 16.2 billion in 2022 to KRW 45 billion in 2025, and net profit attributable to controlling shareholders rose from KRW 9.13 billion to KRW 27.8 billion. Both rose three consecutive years from 2023 through 2025.

Operating cash flow stayed positive at KRW 33.7 billion, KRW 25.8 billion and KRW 34.7 billion in 2023 to 2025, and the cash backing is cited as a bullish point.

Overseas sales built around feed additives

Brokerage reports cite feed additives at 78.95% of sales. Overseas sales were in the low-teens percent in 2023, and a brokerage estimate cited in press reports puts the share above 70% in 2026. The January 2026 BioMatrix deal added pet distribution experience. Bulls argue that higher North American additive share could lift both sales scale and profitability.

A more concrete shareholder return plan

The 2026 corporate value enhancement plan, decided on March 31, 2026, includes a 25% rise in the dividend amount for the prior fiscal year. The company said it qualifies as a high-dividend company under the tax special act.

The plan also targets capital efficiency and a stronger financial structure, and the dividend increase alongside earnings growth is a point bulls cite.

09

Bear factors

Softer Q3 earnings

Q3 2026 net profit attributable to controlling shareholders was KRW 1.08 billion, down 89.4% from the prior quarter and 87.0% from a year earlier, and it declined for two consecutive quarters. Operating profit also fell 23.4% from the prior quarter to KRW 11.5 billion. Bears point to revenue rising to KRW 140 billion without profit following.

Balance sheet leverage

Total liabilities of KRW 213.9 billion at the end of 2025 exceeded total equity of KRW 113.6 billion. The debt-to-equity ratio fell from 305.4% in 2024 to 188.4% in 2025 but remains above 100%. Bears argue that the debt burden from acquisitions could narrow financial room if it overlaps with weaker profit.

Volatile margins

The operating margin was 10.4% in 2022, 12.5% in 2023, 8.4% in 2024 and 9.4% in 2025. Even with revenue reaching KRW 384.3 billion and KRW 476.9 billion, the margin did not return to its 2023 level. Bears note that margins remain volatile, which could slow how quickly sales growth converts into profit.

10

Risk factors

Raw materials, grain prices and FX

Grain prices and the exchange rate move both costs and selling prices. Brokers see the high exchange rate as favorable, but a reversal could reduce the won value of overseas profit. Lower grain prices support farm purchasing power, yet a rebound in raw material costs could compress margin spreads.

Acquisition integration and overseas management

The company has 11 consolidated subsidiaries, and the Devenish consolidation in 2024 and the BioMatrix deal in 2026 expanded the number of overseas units to manage. Acquisition-related due diligence and new-entity costs have already affected reported results.

If integration of cost structures and sales channels is delayed, the expected synergies could take longer to show.

Float structure and share price volatility

Easy Holdings and three related parties hold 51.53% as of October 6, 2026, which may limit the number of shares traded on the market. As a small-cap stock, the price can move sharply on light volume, and this structure can add volatility regardless of earnings announcements.

11

What to watch next

  1. Late March 2027

    The 2026 annual business report and confirmed Q4 and full-year 2026 results. The check is whether the Q3 drop in controlling-shareholder profit came from non-operating items or taxes, and how the overseas sales share appears in the filing.

  2. Around the March 2027 annual general meeting

    The dividend decision and progress under the value enhancement plan, including whether the 25% increase in the prior-year dividend amount was implemented.

  3. Mid-May 2027

    The Q1 2027 earnings release. The prior-year Q1 results were released on May 15, so mid-May is the next quarterly checkpoint, including whether the two-quarter decline in controlling-shareholder profit stops.

12

Overall view

Easy BIO has grown sales and operating profit since 2022, and operating profit and net profit attributable to controlling shareholders rose for three consecutive years from 2023 through 2025. Feed additives account for 78.95% of sales according to brokerage reports, and the mix is shifting toward overseas sales.

However, Q3 2026 revenue rose 19.8% while net profit attributable to controlling shareholders fell to KRW 1.08 billion, making earnings durability the next point to check. The operating margin was 8.4% in 2024 and 9.4% in 2025, below 12.5% in 2023, so margin stability also needs watching.

Total liabilities of KRW 213.9 billion exceed total equity of KRW 113.6 billion at the end of 2025, and the balance sheet remains a burden following acquisitions. The shareholder return plan includes a 25% increase in the prior-year dividend amount.

The next checkpoints are the Q4 and full-year 2026 results in the annual business report and the Q1 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.wisereport.co.kr
  2. vegannews.co.kr
  3. digitaltoday.co.kr
  4. dailyinvest.kr
  5. biotimes.co.kr
  6. comp.fnguide.com
  7. topdaily.kr
  8. ksdaily.co.kr
  9. pinpointnews.co.kr
  10. investing.com
  11. biotimes.co.kr
  12. ksdaily.co.kr
  13. comp.fnguide.com
  14. news.nate.com
  15. news.abbvie.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis